Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBT Margin: 2017-2025

Historic EBT Margin for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to 16.97%.

  • Puma Biotechnology's EBT Margin fell 862.00% to 16.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.58%, marking a year-over-year increase of 446.00%. This contributed to the annual value of 10.46% for FY2024, which is 83.00% up from last year.
  • Latest data reveals that Puma Biotechnology reported EBT Margin of 16.97% as of Q3 2025, which was up 44.32% from 11.76% recorded in Q2 2025.
  • Puma Biotechnology's 5-year EBT Margin high stood at 25.59% for Q3 2024, and its period low was -96.52% during Q3 2021.
  • Its 3-year average for EBT Margin is 8.95%, with a median of 10.71% in 2023.
  • As far as peak fluctuations go, Puma Biotechnology's EBT Margin plummeted by 3,453bps in 2021, and later soared by 9,601bps in 2022.
  • Over the past 5 years, Puma Biotechnology's EBT Margin (Quarterly) stood at 8.01% in 2021, then plummeted by 1,407bps to -6.06% in 2022, then soared by 2,380bps to 17.74% in 2023, then spiked by 298bps to 20.72% in 2024, then tumbled by 862bps to 16.97% in 2025.
  • Its EBT Margin stands at 16.97% for Q3 2025, versus 11.76% for Q2 2025 and 7.10% for Q1 2025.